Neuromuscular HOMEepAGE

neuromuscular.wustl.edu

/

I. Clinical Indications for Measurement of anti-MAG antibodies

Immune/Antibody

View full entry on WUSTL Neuromuscular

antibody/mag.html#I. Clinical Indications for Measurement of anti-MAG antibod

Overview

From WUSTL Neuromuscular

Diagnostic work-ups of adult onset, symmetric polyneuropathies, especially with: Clinical features Predominantly distal numbness ± weakness Symmetry Sensory > motor Age > 50 Electrodiagnostic studies: Demyelination, usually with Prolonged distal latencies, and No focal conduction block Serum IgM M-protein Treatment follow-up: Document necessary & sufficient dose of immunosuppression Best prognosis: Anti-MAG antibody titers are reduced by > 60% Characteristics that increase the likelihood of a positive test Age > 50 Gait disorder Tremor Functionally significant disability from motor or sensory

Related Conditions

Shared genes

Antibodies vs Glycolipids & Glycoproteins

Axonal Sensory Neuropathies with Serum IgM binding to Trisulfated Heparin Disaccharide (TS-HDS)

HDSDISACCHARIDEMAG

II. Results with Specificity and Sensitivity for Sensory-Motor Neuropathies

III. Testing Laboratory Standards for anti-MAG Antibodies.

IV. Interpretations of Confirmed Positive anti-MAG Results

IV. Positive Result: Clinical Utility and Interpretations

Monoclonal Gammopathies of Unknown Significance (& Other)

Myelin Glycoproteins

External Resources

WUSTL Neuromuscular

Washington University Disease Center

Biomedical Literature

NCBI Expert-Authored Reviews

Portal for Rare Diseases

National Organization for Rare Disorders

Data sourced from the Washington University Neuromuscular Disease Center. For clinical use, always refer to primary sources.